Liquidia collaborates with Sandoz and Mainbridge to develop new pump for treprostinil; promotion deal extended to 2032

Liquidia Corp

Development agreement with Mainbridge to create new subcutaneous pump for treprostinil injection, targeting 510(k) submission in 2023.
Sandoz and Liquidia will equally split development costs; Mainbridge to perform all development, validation, and testing.
Promotion agreement for Treprostinil Injection extended by five years, now through December 31, 2032.
New pump aims to reduce single-source dependence on existing CADD-MS 3 system for PAH patients.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Liquidia Corp entered into Pump Development Agreement with Mainbridge Health Partners, LLC and Sandoz Inc. (effective 2022-12-01).

Action: entry
Agreement: collaboration
Counterparty: Mainbridge Health Partners, LLC and Sandoz Inc.
Effective: 2022-12-01

Exact text from the filing

On December 1, 2022, Liquidia PAH, LLC, a Delaware limited liability company (“Liquidia PAH”), a wholly-owned subsidiary of Liquidia Corporation, a Delaware corporation (the “Company”), entered into a Device Development and Supply Agreement (the “Pump Development Agreement”) with Mainbridge Health Partners, LLC (“Mainbridge”) and Sandoz Inc. (“Sandoz”).

View on SEC.gov

Browse all material agreements →

Liquidia Corp filing history →

Source: SEC EDGAR

accession 0001104659-22-124592

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.